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Interest in the phenomenon of pseudoprogression has rekindled in oncology with the 
development of immunotherapeutics for many cancers including those involving the 
central nervous system. Pseudoprogression refers primarily to imaging changes that 
mimic progressive tumor, but are due to other etiologies that most commonly include 
inflammation related to therapy. Ramifications for patients and clinicians associated with 
failure to identify pseudoprogression are substantive and include premature 
discontinuation of an effective therapy and overestimating the efficacy of a subsequent 
therapy. The latter may generate misleading results for uncontrolled phase II trials 
evaluating salvage therapies. Among patients with glioma, including glioblastoma, the 
most common and difficult to treat type of glioma, pseudoprogression has been reported 
in up to  30% of patients following radiation combined with temozolomide chemotherapy 
(RT/TMZ) with most cases noted within 3 months, although delayed cases have been 
described.1 Careful consideration of timimg of reference scans and of all interventions in 
between two MRI scans is required to arrive at this diagnosis. Pseudoprogression can be 
accompanied by new or worsened neurologic deficits, but many reports note minimal 
neurologic changes despite disproportionately worsened imaging findings. 
Pseudoprogression may develop more frequently among patients with a methylated O6-
methylguanine DNA methyltransferase (MGMT) promoter,2 reflecting the enhanced 
sensitivity of such tumors to TMZ, but this link has not been confirmed. Advanced 
magnetic resonance imaging sequences such as diffusion and perfusion imaging, and 
various metabolic imaging modalities including positron emission tomography and 
spectroscopy, may provide insight into whether progressive imaging findings reflect true 
versus pseudo progression,3 but none are definitive. Most patients in this situation 
undergo close follow-up imaging while continuing treatment, given that 
pseudoprogression ultimately stabilizes whereas true progression steadily worsens. 
Surgery can be informative, but biopsies should be interpreted cautiously as sampling 
artifact may not accurately account for heterogeneity of histopathologic changes. Of note, 
continuation of treatment despite suspected pseudoprogression precludes distinctions 
between “true” pseudoprogression and delayed treatment response. 
The Radiologic Assessment in Neuro-Oncology (RANO) criteria were drafted to provide 
guidance for clinicians confronted with pseudoprogression and to standardize how this 
situation is handled in clinical trials.4 RANO specifies that progressive disease can not be 
determined within three months of completing concomitant RT/TMZ unless confirmed 
surgically or by new enhancing disease outside the radiation field. Survival is better for 
patients with pseudoprogression compared to those with early true progression, but is 
comparable to patients without pseudoprogression or early true progression.5 
In the current immune-oncology era, there is concern that robust immunologic 
intratumoral infiltrates could lead to pseudoprogressive imaging findings. In addition, 
progressive imaging changes may reflect initial true tumor progression that ultimately 
becomes controlled by a delayed immune response. The immune-related Response 
Criteria (irRC) were generated to address the possibility of pseudoprogression, including 
the appearance of new lesions following immunotherapy.6 Specifically, the irRC criteria 
call for immunotherapy continuation with follow-up imaging to confirm progression. 
Among 227 patients with advanced melanoma treated with the CTLA-4 inhibitor 
ipilimumab, 10% of patients who met WHO criteria for tumor progression demonstrated 
evidence of subsequent therapeutic benefit when assessed using irRC. With the 
widespread use of immune checkpoint inhibitors, the frequency of pseudoprogression 
appears highest in advanced melanoma (3-16%), but is lower in other solid tumors (1-
9%).7 Of note, the frequency and kinetics of pseudoprogression for other immunotherapy 
treatments such as vaccines or adoptive T cell agents, as well as for the growing number 
of combinatorial regimens, remains undefined. Importantly, irRC considerations have 
been incorporated in regulatory guidance materials.8,9 
Analogous to the irRC, the Immunotherapy Response Assessment in Neuro-Oncology 
(iRANO) criteria provide guidance regarding management of possible pseudoprogression 
among patients with primary and metastatic brain tumors undergoing immunotherapy.10 
iRANO empirically stipulates a three month window for confirmation of progression on 
follow-up imaging, and further advises that progressive imaging changes beyond six 
months after immunotherapy initiation are more likely true tumor progression. To date, 
few neuro-oncology trials evaluating immunotherapies have reported outcome. Among 
these, including phase 3 studies of anti-PD-1 antibody for recurrent glioblastoma11 and 
an EGFRvIII peptide vaccine for newly diagnosed patients,12 minimal therapeutic benefit 
has been observed with rare radiographic responses and lack of improved progression-
free or overall survival. In the context of such negative outcomes, the meaning and impact 
of pseudoprogression becomes moot. Nonetheless, across the spectrum of ongoing trials 
as well as compassionate use of immunotherapeutic agents, anecdotal reports of 
pseudoprogression are emerging among neuro-oncology patients. Future neuroimaging 
and histopathologic data are needed to define the biologic basis and potential prognostic 
significance of pseudoprogression in a disease- and treatment-specific manner. Neuro-
oncologists remain hopeful that immunotherapy will have an impact for their patients, and 
that a better understanding of pseudoprogression may aid in tailoring novel treatment 
approaches.  
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